Danaher

NYSE: DHR
New York Stock Exchange
Healthcare Diagnostics & Research
Global Rank
#151
Country Rank
#87
Market Cap
129.93 B
Price
181.46
Change (%)
2.39%
Volume
7.43 M

Danaher's latest marketcap:

129.93 B

As of 09/26/2025, Danaher's market capitalization has reached $129.93 B. According to our data, Danaher is the 151th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 129.93 B
Revenue (ttm) 24.01 B
Net Income (ttm) 3.41 B
Shares Out 716.05 M
EPS (ttm) 4.71
Forward PE 22.36
Ex-Dividend Date 09/26/2025
Earnings Date 10/21/2025
Market Cap Chart
Data Updated: 09/26/2025

Danaher's yearly market capitalization.

Danaher has seen its market value grow from $7.33 B to $129.93 B since 1998, representing a total increase of 1,672.40% and an annual compound growth rate (CAGR) of 11.35%.
Date Market Cap($) Change (%) Global Rank
09/26/2025 $129.93 B -17.74% 151
12/31/2024 $165.8 B -3.01% 84
12/29/2023 $170.94 B -11.53% 69
12/30/2022 $193.22 B -17.82% 48
12/31/2021 $235.1 B 48.98% 49
12/31/2020 $157.8 B 43.14% 69
12/31/2019 $110.24 B 52.53% 93
12/31/2018 $72.28 B 11.94% 118
12/29/2017 $64.57 B 19.92% 159
12/30/2016 $53.84 B -15.41% 160

Company Profile

About Danaher Corporation

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services globally, with a strong presence in the United States and China. The company operates through three key segments:

Business Segments

  • Biotechnology Segment: Provides bioprocessing technologies, consumables, and services for therapeutic development and manufacturing. This includes cell culture media, chromatography resins, filtration solutions, lab-scale protein purification tools, and diagnostic assay development reagents.
  • Life Sciences Segment: Offers advanced instruments and solutions such as mass spectrometers, flow cytometry systems, genomics tools, microscopes, and protein consumables. Brands under this segment include ABCAM, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, and SCIEX.
  • Diagnostics Segment: Delivers clinical instruments, consumables, and software for hospitals, labs, and critical care settings. Products cover clinical chemistry, immunoassay, hematology, and microbiology.

Company Background

Originally founded in 1969 as Diversified Mortgage Investors, Inc., the company rebranded as Danaher Corporation in 1984. Today, it is headquartered in Washington, D.C., and continues to drive innovation across biotechnology, life sciences, and diagnostics.

Frequently Asked Questions

  • What is Danaher's (DHR) current market cap?
    As of 09/26/2025, Danaher (including the parent company, if applicable) has an estimated market capitalization of $129.93 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • Danaher global market capitalization ranking is approximately 151 as of 09/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.